Bradley T. Sumrall
Expertise in
69
conditions

Dr. Bradley T. Sumrall

Hematology | Oncology
5430 Bowman Road, 
Macon, GA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
69
conditions
5430 Bowman Road, 
Macon, GA 

Overview

Bradley Sumrall is a Hematologist and an Oncologist practicing medicine in Macon, Georgia.

Dr. Sumrall is highly rated in 69 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Thrombocytopenia, and Idiopathic Neutropenia.

Dr. Sumrall is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 14 clinical trials. Dr. Sumrall is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Specialist in GA

Board Certifications

American Board Of Internal Medicine

Fellowships

Ochsner Medical Institution, Medical Oncology, 2013

Hospital Affiliations

Coliseum Medical Centers, Llc, Dba
Atrium Health Navicent The Medical Center
Piedmont Macon North Hospital
Emory Houston Hospital Warner Robins
Northside Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Central Georgia Cancer Care
5430 Bowman Road, Macon, GA 31210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
View 9 Less Clinical Trials

4 Total Publications

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.
Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2025
Similar Doctors
Expertise in
60
conditions
Dr. Harry F. Moore
Hematology | Oncology
Expertise in
60
conditions
Dr. Harry F. Moore
Hematology | Oncology
Referral may be required
Before you request

Central Georgia Cancer Care

5430 Bowman Road, 
Macon, GA 
 (0.1 miles away)
478-743-7068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harry Moore is a Hematologist and an Oncologist practicing medicine in Macon, Georgia. Dr. Moore is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Moore is board certified in American Board Of Internal Medicine - Medical Oncology and American Board Of Internal Medicine. Dr. Moore is currently accepting new patients.

Expertise in
48
conditions
Dr. Linda K. Hendricks
Hematology | Oncology
Expertise in
48
conditions
Dr. Linda K. Hendricks
Hematology | Oncology
Referral may be required
Before you request

Central Georgia Cancer Care

5430 Bowman Road, 
Macon, GA 
 (0.1 miles away)
478-743-7068
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Linda Hendricks is a Hematologist and an Oncologist practicing medicine in Macon, Georgia. Dr. Hendricks is highly rated in 48 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Idiopathic Neutropenia, Agranulocytosis, and Chronic Familial Neutropenia. Dr. Hendricks is board certified in American Board Of Internal Medicine - Medical Oncology and American Board Of Internal Medicine - Hospice & Palliative Medicine. Dr. Hendricks is currently accepting new patients.

Expertise in
37
conditions
Dr. Premila Malhotra
Hematology | Oncology
Expertise in
37
conditions
Dr. Premila Malhotra
Hematology | Oncology
Referral may be required
Before you request

Georgia Cancer Specialists

308 Coliseum Drive, Suite 120, 
Macon, GA 
 (8.0 miles away)
478-745-6130
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Premila Malhotra is a Hematologist and an Oncologist practicing medicine in Macon, Georgia. Dr. Malhotra is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Thrombocytopenia, and Pleuropulmonary Blastoma. Dr. Malhotra is board certified in American Board Of Internal Medicine - Hematology and American Board Of Internal Medicine - Medical Oncology. Dr. Malhotra is currently accepting new patients.

Frequently Asked Questions about Dr. Bradley T. Sumrall

How do I make an appointment with Dr. Bradley T. Sumrall?

You can book an appointment with Dr. Bradley T. Sumrall by calling their office at 478-743-7068. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bradley T. Sumrall a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bradley T. Sumrall is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bradley T. Sumrall specialize in?

While Dr. Bradley T. Sumrall is a Hematology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Bradley T. Sumrall participate in research or clinical trials?

Yes. Dr. Bradley T. Sumrall has published 4 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Bradley T. Sumrall's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bradley T. Sumrall accept my insurance?

Dr. Bradley T. Sumrall accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 478-743-7068 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sumrall's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 53 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile